| 10 | 0 | 30 |
| 下载次数 | 被引频次 | 阅读次数 |
溴结构域蛋白4(Bromodomain-containing protein 4, BRD4)是BET蛋白家族的重要成员，其主要功能是识别并结合组蛋白上的乙酰化赖氨酸，作为“表观遗传阅读器”在调控基因转录中发挥核心作用。近年研究发现，BRD4在肾纤维化、肾细胞癌、狼疮性肾炎及糖尿病肾脏病等多种肾脏疾病的发病机制中扮演了关键角色。目前该领域的研究已从机制探索进入靶向干预阶段，多项实验证据表明BRD4抑制剂能有效减轻肾脏病理损伤并改善肾功能。本文系统阐述了BRD4的分子结构与调控机制，重点总结了其在不同类型肾脏疾病中的致病作用及BRD4抑制剂的治疗潜力，旨在揭示BRD4作为肾脏疾病精准治疗分子靶点的潜力，并展望其临床应用前景。
Abstract：Bromodomain-containing protein 4(BRD4) is a key member of the BET protein family. Its primary function is to recognize and bind to acetylated lysine residues on histones, acting as an epigenetic "reader" that plays a central role in transcriptional regulation. Recent studies have revealed that BRD4 plays a critical role in the pathogenesis of various kidney diseases, including renal fibrosis, renal cell carcinoma, lupus nephritis, and diabetic kidney disease. Currently, research in this field has transitioned from mechanistic exploration to targeted intervention, with multiple lines of experimental evidence indicating that BRD4 inhibitors can effectively alleviate renal pathological injury and improve kidney function. This review systematically elaborates on the molecular structure and regulatory mechanisms of BRD4, summarizes its pathogenic roles in different types of kidney diseases and the therapeutic potential of BRD4 inhibitors, and aims to highlight the clinical prospects of BRD4 as a molecular target for the precision treatment of renal disorders.
[1]Foreman K J,Marquez N,Dolgert A,et al. Forecasting life expectancy,years of life lost,and all-cause and causespecific mortality for 250 causes of death:reference and alternative scenarios for 2016-40 for 195 countries and territories[J]. Lancet,2018,392(10159):2052-2090.
[2]Huang R,Fu P,Ma L. Kidney fibrosis:from mechanisms to therapeutic medicines[J]. Sig Transduct Target Ther,2023,8(1):129.
[3]Morgado-Pascual J L,Rayego-Mateos S,Tejedor L,et al.Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases[J]. Front Pharmacol,2019,10:1315.
[4]Guo J,Zheng Q,Peng Y. BET proteins:Biological functions and therapeutic interventions[J]. Pharmacol Ther,2023,243:108354.
[5]Huang J,Zhao N,An C,et al. Development of a potent BET inhibitor for the treatment of renal fibrosis[J]. Eur J Med Chem,2025,295:117822.
[6]Filippakopoulos P,Qi J,Picaud S,et al. Selective inhibition of BET bromodomains[J]. Nature,2010,468(7327):1067-1073.
[7]Ali H A,Li Y,Bilal A H M,et al. A comprehensive review of BET protein biochemistry,physiology,and pathological roles[J]. Front Pharmacol,2022,13:818891.
[8]Korb E,Wilkinson A W,Delgado R N,et al. BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice[J]. Nat Neurosci,2015,18(10):1464-1473.
[9]Cheung K L,Kim C,Zhou M M. The functions of BET proteins in gene transcription of biology and diseases[J].Front Mol Biosci,2021,8:728777.
[10]Mochizuki K,Nishiyama A,Jang M K,et al. The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase[J]. J Biol Chem,2008,283(14):9040-9048.
[11]Wang N,Wu R,Tang D,et al. The BET family in immunity and disease[J]. Sig Transduct Target Ther,2021,6(1):23.
[12]Ruiz-Ortega M,Rayego-Mateos S,Lamas S,et al. Targeting the progression of chronic kidney disease[J]. Nat Rev Nephrol,2020,16(5):269-288.
[13]Lan H Y. Diverse roles of TGF-β/Smads in renal fibrosis and inflammation[J]. Int J Biol Sci,2011,7(7):1056-1067.
[14]Yang M,Li J,Huang X,et al. AT1,a small molecular degrader of BRD4 based on proteolysis targeting Chimera technology alleviates renal fibrosis and inflammation in diabetic nephropathy[J]. Bioorg Chem,2025,156:108184.
[15]Rayego-Mateos S,Morgado-Pascual J L,Suarez-Alvarez B S,et al. The BET bromodomain inhibitor jq1 diminished renal fibrosis[J]. Nephrol Dial Transplant,2016,31(suppl_1):i102.
[16]Xiong C,Masucci M V,Zhou X,et al. Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis[J]. Oncotarget,2016,7(43):69291-69308.
[17]Zhou B,Mu J,Gong Y,et al. Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF-β-mediated Nox4 expression[J]. Redox Biol,2017,11:390-402.
[18]Liu H,Wang L,Weng X,et al. Inhibition of Brd4 alleviates renal ischemia/reperfusion injury-induced apoptosis and endoplasmic reticulum stress by blocking FoxO4-mediated oxidative stress[J]. Redox Biol,2019,24:101195.
[19]Sun L,Liu J,Yuan Y,et al. Protective effect of the BET protein inhibitor JQ1 in cisplatin-induced nephrotoxicity[J]. Am J Physiol Ren Physiol,2018,315(3):F469-F478.
[20]Yu H,Lin L,Zhang Z,et al. Targeting NF-κB pathway for the therapy of diseases:mechanism and clinical study[J]. Sig Transduct Target Ther,2020,5(1):209.
[21]Hajmirza A,Emadali A,Gauthier A,et al. BET family protein BRD4:an emerging actor in NFκB signaling in inflammation and cancer[J]. Biomedicines,2018,6(1):16.
[22]Xiong C,Deng J,Wang X,et al. Pharmacologic targeting of BET proteins attenuates hyperuricemic nephropathy in rats[J]. Front Pharmacol,2021,12:636154.
[23]Wang X,Zhou Y,Peng Y,et al. Bromodomain-containing protein 4 contributes to renal fibrosis through the induction of epithelial-mesenchymal transition[J]. Exp Cell Res,2019,383(2):111507.
[24]Saiz M L,Lozano-Chamizo L,Florez A B,et al. BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury[J]. Biomedecine Pharmacother,2024,174:116492.
[25]Wang M,Huang Z,Li X,et al. Apabetalone,a BET protein inhibitor,inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis[J]. Pharmacol Res,2024,207:107306.
[26]Wang X,Yang S,Li S,et al. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents[J]. Gut,2020,69(12):2131-2142.
[27]Tan Z,Wang Z,Zeng Q,et al. Natural intestinal metabolite xylitol reduces BRD4 levels to mitigate renal fibrosis[J]. Clin Transl Sci,2024,17(3):e13770.
[28]Capitanio U,Montorsi F. Renal cancer[J]. Lancet,2016,387(10021):894-906.
[29]Owens B. Kidney cancer[J]. Nature,2016,537(7620):S97.
[30]Rini B I,Campbell S C,Escudier B. Renal cell carcinoma[J]. Lancet,2009,373(9669):1119-1132.
[31]Zhan Y,Liu Y,Yang R,et al. CircPTEN suppresses human clear cell renal carcinoma progression and resistance to mTOR inhibitors by targeting epigenetic modification[J]. Drug Resist Updat,2023,71:101003.
[32]Dhimolea E,de Matos Simoes R,Kansara D,et al. An embryonic diapause-like adaptation with suppressed myc activity enables tumor treatment persistence[J].Cancer Cell,2021,39(2):240-256. e11.
[33]Sakaguchi T,Yoshino H,Sugita S,et al. Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma[J]. Oncotarget,2018,9(33):23003-23017.
[34]Tan Y F,Wang M,Chen Z Y,et al. Inhibition of BRD4prevents proliferation and epithelial-mesenchymal transition in renal cell carcinoma via NLRP3 inflammasomeinduced pyroptosis[J]. Cell Death Dis,2020,11(4):239.
[35]Yin M,Guo Y,Hu R,et al. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction[J]. Nat Commun,2020,11(1):1833.
[36]Xu M,Xu L,Wang Y,et al. BRD4 inhibition sensitizes renal cell carcinoma cells to the PI3K/mTOR dual inhibitor VS-5584[J]. Aging,2020,12(19):19147-19158.
[37]Durcan L,O’Dwyer T,Petri M. Management strategies and future directions for systemic lupus erythematosus in adults[J]. Lancet,2019,393(10188):2332-2343.
[38]Kiriakidou M,Ching C L. Systemic lupus erythematosus[J]. Ann Intern Med,2020,172(11):ITC81-ITC96.
[39]Kong I Y,Rimes J S,Light A,et al. Temporal analysis of Brd4 displacement in the control of B cell survival,proliferation,and differentiation[J]. Cell Rep,2020,33(3):108290.
[40]Devaiah B N,Lewis B A,Cherman N,et al. BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA Polymerase II carboxy-terminal domain[J]. Proc Natl Acad Sci U S A,2012,109(18):6927-6932.
[41]Lee M B,Lee J H,Hong S H,et al. JQ1,a BET inhibitor,controls TLR4-induced IL-10 production in regulatory B cells by BRD4-NF-κB axis[J]. BMB Rep,2017,50(12):640-646.
[42]Zeng S,Qiu Q,Zhou Y,et al. The suppression of Brd4 inhibits peripheral plasma cell differentiation and exhibits therapeutic potential for systemic lupus erythematosus[J]. Int Immunopharmacol,2022,103:108498.
[43]Wei S,Sun Y,Sha H. Therapeutic targeting of BET protein BRD4 delays murine lupus[J]. Int Immunopharmacol,2015,29(2):314-319.
[44]Yu C,Li P,Dang X,et al. Lupus nephritis:new progress in diagnosis and treatment[J]. J Autoimmun,2022,132:102871.
[45]Tuttle K R,Levin A,Nangaku M,et al. Safety of empagliflozin in patients with type 2 diabetes and chronic kidney disease:pooled analysis of placebo-controlled clinical trials[J]. Diabetes Care,2022,45(6):1445-1452.
[46]Liu R,Zhong Y,Li X,et al. Role of transcription factor acetylation in diabetic kidney disease[J]. Diabetes,2014,63(7):2440-2453.
[47]Zuo H,Wang S,Feng J,et al. BRD4 contributes to highglucose-induced podocyte injury by modulating Keap1/Nrf2/ARE signaling[J]. Biochimie, 2019, 165:100-107.
[48]Shorstova T,Foulkes W D,Witcher M. Achieving clinical success with BET inhibitors as anti-cancer agents[J]. Br J Cancer,2021,124(9):1478-1490.
[49]Schreiber J,Liaukouskaya N,Fuhrmann L,et al. BET proteins regulate expression of Osr1 in early kidney development[J]. Biomedicines,2021,9(12):1878.
[50]Lai J,Liu Z,Zhao Y,et al. Anticancer effects of IBET151,an inhibitor of bromodomain and extra-terminal domain proteins[J]. Front Oncol,2021,11:716830.
基本信息:
中图分类号:R692
引用信息:
[1]万书径,于赵龙,姜英杰,等.溴结构域蛋白4在肾脏疾病中的研究进展[J].赣南医科大学学报().
基金信息:
国家自然科学基金项目(32460167)
2026-06-30
2026-06-30
2026-06-30